Structurally Modified Analogues of Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP) As Future Antidiabetic Agents

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|10|29|3651-3662

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.10, Iss.29, 2004-11, pp. : 3651-3662

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Potential Role of Glucagon-Like Peptide-1 (GLP-1) in Neuroprotection

By Hölscher Christian  

CNS Drugs, Vol. 26, Iss. 10, 2012-10 ,pp. : 871-882

Adis International

Access to resources Recommend Favorite

NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs

By Ribel U.   Larsen M.O.   Rolin B.   Carr R.D.   Wilken M.   Sturis J.   Westergaard L.   Deacon C.F.   Knudsen L.B.  

European Journal of Pharmacology, Vol. 451, Iss. 2, 2002-09 ,pp. : 217-225

Elsevier

Access to resources Recommend Favorite

Glucagon-like Peptide-1 Analogues for Type 2 Diabetes Mellitus: Current and Emerging Agents

By Gallwitz Baptist  

Drugs, Vol. 71, Iss. 13, 2011-09 ,pp. : 1675-1688

Adis International

Access to resources Recommend Favorite

Metformin increases the plasma level of glucagon-like peptide-1 (GLP-1) and does not inhibit dipeptidyl peptidase-IV

By  

Inpharma, Vol. 1, Iss. 1607, 2007-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes

By Bak Ann Mosegaard   Egefjord Lærke   Gejl Michael   Steffensen Charlotte   Stecher Chalotte Willemann   Smidt Kamille   Brock Birgitte   Rungby Jørgen  

Expert Opinion on Therapeutic Targets, Vol. 15, Iss. 10, 2011-10 ,pp. : 1153-1162

Informa Healthcare

Access to resources Recommend Favorite